Marksans Pharma Q1 FY26 Earnings Results: Revenue Up 5% YoY to ₹620 Crore

Marksans Pharma reported operating revenue of ₹620 crore in Q1FY26, up 5% from last year. Growth was mainly driven by new product launches in the US in gastrointestinal, pain management, and digestive health categories.

Gross profit stood at ₹358.2 crore, rising 8.9% YoY, with margins improving to 57.8% due to lower input costs and liquidation of higher-cost inventories. EBITDA came in at ₹100.1 crore, with a 16.1% margin. Earnings per share (EPS) was ₹1.3.

Business Performance by Region

United States & North America:

• Revenue: ₹327.6 crore
• Growth supported by new product launches and easing raw material costs.

United Kingdom & Europe:

• Revenue: ₹203.8 crore
• Some products saw price pressure, but four high-margin liquid products were launched to strengthen the portfolio.

Australia & New Zealand:

• Revenue: ₹57 crore
• Growth slowed due to strong performance in the previous quarter and destocking, but recovery signs are visible.

Rest of the World (RoW):

• Revenue: ₹31.6 crore
• Performance aided by favorable market conditions and strategic shipment timings.

Operational & Strategic Highlights

• Cash balance as of June 30, 2025: ₹711 crore.
• Net cash from operations: ₹48.7 crore.
• Capex in Q1FY26: ₹37.8 crore.
• Working capital cycle: ~159 days, mainly due to frontloading shipments to the US ahead of expected tariffs.
• R&D spend: ₹12.1 crore (2% of revenue).

About Marksans Pharma

Marksans Pharma manufactures and markets generic pharmaceutical formulations globally. Its plants are approved by major regulators like USFDA, UKMHRA, and Australian TGA. Its portfolio spans cardiovascular, CNS, antidiabetic, pain management, gastroenterological, and anti-allergy therapies.

Read More: ICICI Bank Raises Minimum Average Balance for New Savings Accounts Opened After Aug 1, 2025.

Marksans Pharma Share Price Movement

As of 13 August 2025, at 2:08 PM IST, Marksans Pharma share price (NSE: MARKSANS) was trading at ₹184.45, down ₹2.29 or 1.23% for the day. The stock opened at ₹188.00, touched a high of ₹190.00, and a low of ₹183.23 during the session. The company has a market capitalisation of ₹8,360 crore, a price-to-earnings (P/E) ratio of 21.96, and offers a dividend yield of 0.43%, with a quarterly dividend payout of ₹0.20 per share. Over the past 52 weeks, the stock has recorded a high of ₹358.70 and a low of ₹171.00.

Conclusion

Marksans Pharma delivered steady revenue growth in Q1FY26 despite seasonal softness and cost pressures. With strong cash reserves, ongoing product launches, and facility upgrades, the company is well-positioned for sustained growth in FY26 and beyond.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.